EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection

Seung Hyun Baik iD, So Yeon Kim, Young Cheol Na, Jin Mo Cho

Journal of Personalized Medicine · 22.02.2023 · 13 (3) · 383

DOI: 10.3390/jpm13030383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 22.02.2023. Verfasst von Seung Hyun Baik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, International St Mary's Hospital, Catholic Kwandong University, Incheon 22711, Republic of Korea. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Supratotal resection (SupTR) of glioblastoma allows for a superior long-term disease control and increases overall survival. On the other hand, aggressive conventional approaches, including gross total resections (GTR), are limited by the impairment risk of adjacent eloquent areas, which may cause severe postoperative functional morbidity. This study aimed to analyze institutional cases with respect to the potential survival benefits of additional resection, including lobectomy, as a paradigm for SupTR in patients of glioblastoma.

Methods

Between 2014 and 2018, 15 patients with glioblastoma underwent SupTR (GTR and additional lobectomy) at the authors’ institution. The postoperative Karnofsky performance score (KPS), progression-free survival (PFS), and overall survival (OS) were analyzed for the patients.

Results

Patients with SupTR showed significantly prolonged PFS and OS. The median PFS and OS values for the entire study group were 33.5 months (95% confidence intervals (CI): 18.5–57.3 months) and 49.1 months (95% CI: 24.7–86.6 months), respectively. Multivariate analysis revealed that the O6-DNA-methylguanine methyltransferase (MGMT) promoter methylation status was the only predictor for both superior PFS (p = 0.03, OR 5.7, 95% CI 1.0–49.8) and OS (p = 0.04, OR 6.5, 95% CI 1.1–40.2). There was no significant difference between the pre- and postoperative KPS scores.

Conclusions

Our results suggest that SupTR with lobectomy allows for a superior PFS and OS without negatively affecting patient performance. However, due to the small number of patients, further studies that include more patients are needed.

Schlagwörter

Stichwörter der Autor:innen

glioblastomagross total resectionlobectomyoverall survivalsupratotal resection

Autor:innen und Institutionen

  • Department of Neurosurgery, International St Mary's Hospital, Catholic Kwandong University, Incheon 22711, Republic of Korea.

ORCID-Profile: Seung Hyun Baik

Zitieren

APA

Baik, S. H., Kim, S. Y., Na, Y. C., & Cho, J. M. (2023). Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. Journal of Personalized Medicine, 13(3), 383. https://doi.org/10.3390/jpm13030383

Vancouver

Baik SH, Kim SY, Na YC, Cho JM. Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. Journal of Personalized Medicine. 2023;13(3):383. doi:10.3390/jpm13030383

BibTeX
@article{Baik2023,
  author = {Baik, Seung Hyun and Kim, So Yeon and Na, Young Cheol and Cho, Jin Mo},
  title = {Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {383},
  doi = {10.3390/jpm13030383}
}
Kostenlos starten →